The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Johnson & Johnson (JNJ) stock is in focus as the FDA further expands the labeling for its antipsychotic to treat adults with ...

Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for ...

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...

Serial adjunctive ketamine infusions are not more effective than serial midazolam infusions in reducing depressive symptoms ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

Researchers determined the effect of prenatal and early postnatal lead exposure on risk for depression and anxiety in adulthood.

Thriveworks reports seasonal depression peaks in the third week of November, with symptoms affecting cities that experience ...

Shared biological, psychological, and social pathways put patients at risk for both, whether obesity or depression occurs ...